First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
← catalyst calendarNCT05361395 · readout in 740 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
184actual
Sites
44
Countries
Australia, Belgium, Canada +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-24 | actual | When the study began enrolling |
| Primary completion | 2028-08-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-28 | estimated | The whole study's end, after follow-up |
| First posted | 2022-05-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Extensive Stage Small Cell Lung Cancer
Interventions
- Drug: Tarlatamab — also filed as AMG 757
- Drug: Carboplatin
- Drug: Etoposide
- Drug: Atezolizumab — also filed as Tecentriq
- Drug: Durvalumab
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with a Dose Limiting Toxicity (DLT)
measured 24 months
Number of Participants with Treatment-emergent Adverse Events (TEAE)
measured 24 months
Number of Participants with Treatment-related Adverse Events
measured 24 months
Number of Participants with Clinically Significant Changes in Vital Signs
measured 24 months
Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Measurements
measured 24 months
Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests
measured 24 months
Publications
- PMID 40934933 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed